ASLAN Pharmaceuticals Stock Forecast, Price & News

-0.28 (-8.36 %)
(As of 04/12/2021 12:00 AM ET)
Today's Range
Now: $3.07
50-Day Range
MA: $3.79
52-Week Range
Now: $3.07
Volume525,032 shs
Average Volume2.12 million shs
Market Capitalization$116.63 million
P/E RatioN/A
Dividend YieldN/A
ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
ASLAN Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ASLN
Year FoundedN/A



Sales & Book Value

Annual Sales$3 million
Book Value($0.02) per share


Net Income$-47,020,000.00
Return on Equity-10,427.34%


Market Cap$116.63 million
Next Earnings Date5/10/2021 (Estimated)
OptionableNot Optionable


ASLAN Pharmaceuticals Limited (ASLN)
January 27, 2021 |
Intellia (NTLA) Catches Eye: Stock Jumps 7.8%
December 3, 2020 |
Is ASLAN Pharmaceuticals Limited (ASLN) A Good Stock To Buy?
November 29, 2020 |
HorizonTherapeutics (HZNP) Rises YTD on Approvals & Buyouts
November 27, 2020 |
Amgen (AMGN) Ends Deal With Cytokinetics for Heart Candidate
November 24, 2020 |
Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology
November 24, 2020 |
See More Headlines


Overall MarketRank

1.16 out of 5 stars

Medical Sector

949th out of 2,016 stocks

Pharmaceutical Preparations Industry

451st out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.28 (-8.36 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ASLN News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ASLAN Pharmaceuticals (NASDAQ:ASLN) Frequently Asked Questions

Is ASLAN Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ASLAN Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ASLAN Pharmaceuticals stock.
View analyst ratings for ASLAN Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than ASLAN Pharmaceuticals?

Wall Street analysts have given ASLAN Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ASLAN Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,200,000 shares, an increase of 13,693.1% from the February 28th total of 8,700 shares. Based on an average trading volume of 2,120,000 shares, the short-interest ratio is currently 0.6 days.
View ASLAN Pharmaceuticals' Short Interest

When is ASLAN Pharmaceuticals' next earnings date?

ASLAN Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for ASLAN Pharmaceuticals

How were ASLAN Pharmaceuticals' earnings last quarter?

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) released its earnings results on Saturday, November, 14th. The company reported ($0.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01.
View ASLAN Pharmaceuticals' earnings history

How has ASLAN Pharmaceuticals' stock price been impacted by Coronavirus?

ASLAN Pharmaceuticals' stock was trading at $1.59 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ASLN stock has increased by 93.1% and is now trading at $3.07.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ASLN?

1 brokers have issued 12 month price targets for ASLAN Pharmaceuticals' stock. Their forecasts range from $8.00 to $8.00. On average, they expect ASLAN Pharmaceuticals' share price to reach $8.00 in the next year. This suggests a possible upside of 160.6% from the stock's current price.
View analysts' price targets for ASLAN Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are ASLAN Pharmaceuticals' key executives?

ASLAN Pharmaceuticals' management team includes the following people:
  • Dr. Carl Alan Jason Morton Firth, CEO & Exec. Director (Age 48)
  • Mr. Kiran Kumar Asarpota, Chief Operating Officer (Age 42)
  • Mr. Ben Goodger, Gen. Counsel (Age 58)
  • Charlie Hsu, Investor Relations Director
  • Chi-Chin Wang, IR & Corp. Devel. Director
  • Ms. Alison Ward, Chief Devel. Officer
  • Mr. Stephen Doyle, Chief Bus. Officer (Age 48)
  • Dr. Kenneth Kobayashi, Chief Medical Officer

Who are some of ASLAN Pharmaceuticals' key competitors?

What other stocks do shareholders of ASLAN Pharmaceuticals own?

When did ASLAN Pharmaceuticals IPO?

(ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray served as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

What is ASLAN Pharmaceuticals' stock symbol?

ASLAN Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASLN."

How do I buy shares of ASLAN Pharmaceuticals?

Shares of ASLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ASLAN Pharmaceuticals' stock price today?

One share of ASLN stock can currently be purchased for approximately $3.07.

How much money does ASLAN Pharmaceuticals make?

ASLAN Pharmaceuticals has a market capitalization of $116.63 million and generates $3 million in revenue each year. The company earns $-47,020,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

What is ASLAN Pharmaceuticals' official website?

The official website for ASLAN Pharmaceuticals is

Where are ASLAN Pharmaceuticals' headquarters?

ASLAN Pharmaceuticals is headquartered at 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920.

How can I contact ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals' mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company can be reached via phone at 65-6222-4235 or via email at [email protected]

This page was last updated on 4/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.